Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Giredestrant plus everolimus versus physician's choice endocrine therapy plus everolimus in ER-positive, HER2-negative advanced breast cancer
jRCT2061220101Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Giredestrant + everolimus with Physician's choice endocrine therapy + everolimus (2 arms). Primary endpoint: Progression-free survival. Started Apr 2023; status: active, not recruiting.
02
Drugs
giredestranteverolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2061220101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220101.